Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (20)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Almawi, W. Y.
Right arrow Articles by Melemedjian, O. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Almawi, W. Y.
Right arrow Articles by Melemedjian, O. K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2000) 15: 1916-1918
© 2000 European Renal Association-European Dialysis and Transplant Association

Editorial Comments

Clinical and mechanistic differences between FK506 (tacrolimus) and cyclosporin A

Wassim Y. Almawi,1 and Ohannes K. Melemedjian2

1 Department of Laboratory Medicine, St Georges Orthodox Hospital, and 2 Faculty of Arts and Sciences, Haigazian University, Beirut, Lebanon

Introduction

Cyclosporin A (CsA) and FK506 (tacrolimus) are potent immunosuppressive drugs widely used in reducing the incidence and severity of allograft rejection after organ transplantation. Owing to their capacity to antagonize calcineurin activity and hence calcium-dependent T-cell activation [1], both drugs were thought to have identical cellular and molecular effects, despite differences in their structure [2]. This notion was challenged by both clinical and experimental evidence clearly showing that CsA and FK506 immunosuppressive effects are not identical, and that FK506 affects CsA-sensitive and CsA-insensitive T-cell activation pathways. Here we discuss recent findings, including our own, which highlight differences in efficacy and mechanisms between CsA and FK506.

Overview of T-cell activation

T-cell activation is . . . [Full Text of this Article]

Pharmacology of FK506 and CsA

CsA vs FK506 immunosuppressive effects

Conclusion

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Microbiol.Home page
T. Halaby, H. Boots, A. Vermeulen, A. van der Ven, H. Beguin, H. van Hooff, and J. Jacobs
Phaeohyphomycosis Caused by Alternaria infectoria in a Renal Transplant Recipient
J. Clin. Microbiol., May 1, 2001; 39(5): 1952 - 1955.
[Abstract] [Full Text]